Experienced in Alveolar Soft Part Sarcoma

Dr. Jessica M. Clement

Hematology Oncology | Hematology | Oncology
85 Seymour Street, Hartford Hospital Cancer Center, 
Hartford, CT 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Alveolar Soft Part Sarcoma
85 Seymour Street, Hartford Hospital Cancer Center, 
Hartford, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jessica Clement is a Hematologist Oncology specialist and a Hematologist in Hartford, Connecticut. Dr. Clement is rated as an Experienced provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

85 Seymour Street, Hartford Hospital Cancer Center, Hartford, CT 06106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: STP705
Study Phase: Phase 1
View 3 Less Clinical Trials

20 Total Publications

Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Journal: Administration & society
Published: January 06, 2023
Similar Doctors
Distinguished in Alveolar Soft Part Sarcoma
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology
Distinguished in Alveolar Soft Part Sarcoma
Dr. Hari A. Deshpande
Interventional Cardiology | Oncology | Hematology

Yale University

20 York St, 
New Haven, CT 
 (33.8 miles away)
203-785-4638
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hari Deshpande is an Interventional Cardiologist and an Oncologist in New Haven, Connecticut. Dr. Deshpande is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Gastrostomy.

Advanced in Alveolar Soft Part Sarcoma
Dr. Daniel Y. Reuben
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Daniel Y. Reuben
Hematology Oncology | Hematology | Oncology

Hartford Healthcare Medical Group Specialists PLLC

1244 Storrs Rd, Road, 
Storrs, CT 
 (22.9 miles away)
860-724-2579
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Reuben is a Hematologist Oncology specialist and a Hematologist in Storrs, Connecticut. Dr. Reuben is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Melanoma, and Bone Tumor. Dr. Reuben is currently accepting new patients.

Advanced in Alveolar Soft Part Sarcoma
Dr. Matthew L. Hemming
Hematology Oncology | Hematology | Oncology
Advanced in Alveolar Soft Part Sarcoma
Dr. Matthew L. Hemming
Hematology Oncology | Hematology | Oncology

Umass Memorial Medical Group Inc

55 Lake Ave N, 
Worcester, MA 
 (59.6 miles away)
508-334-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Hemming is a Hematologist Oncology specialist and a Hematologist in Worcester, Massachusetts. Dr. Hemming is rated as a Distinguished provider by MediFind in the treatment of Alveolar Soft Part Sarcoma. His top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Alveolar Soft Part Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Hemming is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clement's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile